Other Corporate Information – Page 18

2019-04-02

Regulatory

Alligator Bioscience: New preclinical data for ATOR-1144 demonstrate potential for activation of both the innate and the adaptive immune system, as well as direct anti-tumor effects

Lund, Sweden, April 2, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announce that new preclinical data on the drug candidate ...

2019-03-18

Regulatory

Lund, Sweden, March 18, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announce that they will present preclinical data for th ...

2019-03-07

Regulatory

Dose-escalation study commences with first-in-class bispecific CTLA-4 antibody Lund, Sweden, March 7, 2019 – Alligator Bioscience (Nasdaq St ...

2019-01-29

First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies Lund, Sweden, J ...

2019-01-07

Priority filling submitted RUBY™ bispecific concept has been developed to achieve an outstanding stability, manufacturability and shorter de ...

2018-12-11

Regulatory

A first-in-class bispecific CTLA-4 antibody Lund, Sweden, December 11, 2018 – Alligator Bioscience AB (Nasdaq Stockholm: ATORX) today announ ...

2018-12-10

The science behind the Nobel Prizes in Medicine and Chemistry is the core in Alligator's research and development Read the full magazine ...

2018-11-09

Regulatory

Data Show That ALG.APV-527 Selectively Activates and Enhances Tumor-directed T-cell and Natural Killer (NK) Cell Responses Targets 5T4 Cance ...

2018-11-07

Regulatory

Lund, Sweden, November 7, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that it will receive payments of more than U ...